Association between EPCAM upregulation and clinicopathological parameters and outcomes of breast cancer.

IF 1.1 Q4 ONCOLOGY

International journal of clinical and experimental pathology Pub Date : 2024-11-15 eCollection Date: 2024-01-01 DOI:10.62347/EGXS1506

Nahid Nafissi, Saeed Azad Armaki, Ebrahim Babaee, Pegah Babaheidarian, Elaheh Safari, Soheila Sayad, Samine Saghafinia, Masoumeh Safaee

{"title":"Association between EPCAM upregulation and clinicopathological parameters and outcomes of breast cancer.","authors":"Nahid Nafissi, Saeed Azad Armaki, Ebrahim Babaee, Pegah Babaheidarian, Elaheh Safari, Soheila Sayad, Samine Saghafinia, Masoumeh Safaee","doi":"10.62347/EGXS1506","DOIUrl":null,"url":null,"abstract":"Introduction: EpCAM (epithelial cell adhesion molecule) protein expression was detected in 45 to 90% of breast cancers in different studies, and high expression levels were associated with poor outcomes in several retrospective analyses. This study aims to investigate the relationship between EpCAM and clinicopathological parameters and survival in breast cancer.Methodology: This study was conducted as a Quasi-Experimental Cohort Study to explore 100 breast cancer patients. After the surgical excision of breast cancer, pathology blocks were deparaffinized and subjected to IHC (immunohistochemistry) for EpCAM examination. Using a Roche VENTANA Benchmark GX automated staining instrument and a well-established IHC staining protocol, the expression of EpCAM in breast cancer tissue was assessed. Independent sample T-test and Chi squared and Logistic Regression test with STATA version 17 software were used for data analysis.Results: The difference in the distribution of the negative state of biomarkers (ER = estrogen receptor, PR = Progesterone receptor) and EPCAM positive group was significant (P-value = 0.002) (P-value = 0.006). A statistically insignificant distinction was observed in the distribution of the HER2 (human epidermal growth factor receptor) and EPCAM groups (P-value = 0.198). With 30.95% of those in the EPCAM-positive cohort experienced metastasis or recurrence. ER+ and PR+ decreased the chance of EPCAM positive by 0.25 and 0.29, respectively. HER2+ and Basal like breast cancer increase the chances of EPCAM being positive by 1.9 and 2.08, respectively. Basal like breast cancer increases the odds of EpCAM positive 2.19 times. Similarly, N2 and stage 3 increase the odds of EpCAM positive by 1.95 and 0.5 times, respectively.Conclusion: We found that Basal like breast cancer, HER2+, and stage 3 increase the chance of EpCAM positivity. It seems that EPCAM positive cancer has more chance for recurrence and metastasis.","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"17 11","pages":"421-428"},"PeriodicalIF":1.1000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11626292/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of clinical and experimental pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.62347/EGXS1506","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: EpCAM (epithelial cell adhesion molecule) protein expression was detected in 45 to 90% of breast cancers in different studies, and high expression levels were associated with poor outcomes in several retrospective analyses. This study aims to investigate the relationship between EpCAM and clinicopathological parameters and survival in breast cancer.

Methodology: This study was conducted as a Quasi-Experimental Cohort Study to explore 100 breast cancer patients. After the surgical excision of breast cancer, pathology blocks were deparaffinized and subjected to IHC (immunohistochemistry) for EpCAM examination. Using a Roche VENTANA Benchmark GX automated staining instrument and a well-established IHC staining protocol, the expression of EpCAM in breast cancer tissue was assessed. Independent sample T-test and Chi squared and Logistic Regression test with STATA version 17 software were used for data analysis.

Results: The difference in the distribution of the negative state of biomarkers (ER = estrogen receptor, PR = Progesterone receptor) and EPCAM positive group was significant (P-value = 0.002) (P-value = 0.006). A statistically insignificant distinction was observed in the distribution of the HER2 (human epidermal growth factor receptor) and EPCAM groups (P-value = 0.198). With 30.95% of those in the EPCAM-positive cohort experienced metastasis or recurrence. ER+ and PR+ decreased the chance of EPCAM positive by 0.25 and 0.29, respectively. HER2+ and Basal like breast cancer increase the chances of EPCAM being positive by 1.9 and 2.08, respectively. Basal like breast cancer increases the odds of EpCAM positive 2.19 times. Similarly, N2 and stage 3 increase the odds of EpCAM positive by 1.95 and 0.5 times, respectively.

Conclusion: We found that Basal like breast cancer, HER2+, and stage 3 increase the chance of EpCAM positivity. It seems that EPCAM positive cancer has more chance for recurrence and metastasis.

查看原文本刊更多论文

EPCAM上调与乳腺癌临床病理参数及预后的关系

导读：EpCAM（上皮细胞粘附分子）蛋白在45% - 90%的乳腺癌中表达，在一些回顾性分析中，高表达水平与不良预后相关。本研究旨在探讨EpCAM与乳腺癌临床病理参数及生存率的关系。方法：本研究采用准实验队列研究的方式对100例乳腺癌患者进行研究。乳腺癌手术切除后，病理块脱蜡，免疫组化，进行EpCAM检查。使用罗氏VENTANA Benchmark GX自动染色仪和完善的免疫组化染色方案，评估EpCAM在乳腺癌组织中的表达。数据分析采用独立样本t检验，采用STATA version 17软件进行卡方和Logistic回归检验。结果：生物标志物（ER =雌激素受体，PR =孕激素受体）阴性状态与EPCAM阳性组的分布差异有统计学意义（p值= 0.002）（p值= 0.006）。HER2（人表皮生长因子受体）与EPCAM组的分布差异无统计学意义（p值= 0.198）。epcam阳性队列中有30.95%的患者发生转移或复发。ER+和PR+分别使EPCAM阳性的几率降低0.25和0.29。HER2+和基底样乳腺癌使EPCAM阳性的几率分别增加1.9和2.08。基底样乳腺癌EpCAM阳性的几率增加2.19倍。同样，N2期和3期EpCAM阳性的几率分别增加1.95倍和0.5倍。结论：我们发现基底样乳腺癌、HER2+和3期增加了EpCAM阳性的机会。EPCAM阳性肿瘤有更多的复发和转移机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International journal of clinical and experimental pathology ONCOLOGY-PATHOLOGY

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： The International Journal of Clinical and Experimental Pathology (IJCEP, ISSN 1936-2625) is a peer reviewed, open access online journal. It was founded in 2008 by an international group of academic pathologists and scientists who are devoted to the scientific exploration of human disease and the rapid dissemination of original data. Unlike most other open access online journals, IJCEP will keep all the traditional features of paper print that we are all familiar with, such as continuous volume and issue numbers, as well as continuous page numbers to keep our warm feelings towards an academic journal. Unlike most other open access online journals, IJCEP will keep all the traditional features of paper print that we are all familiar with, such as continuous volume and issue numbers, as well as continuous page numbers to keep our warm feelings towards an academic journal.